Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£1.78|
|52 Week High||UK£1.38|
|52 Week Low||UK£2.36|
|1 Month Change||-3.01%|
|3 Month Change||-12.78%|
|1 Year Change||5.66%|
|3 Year Change||-21.11%|
|5 Year Change||n/a|
|Change since IPO||121.88%|
Recent News & Updates
|CREO||GB Medical Equipment||GB Market|
Return vs Industry: CREO exceeded the UK Medical Equipment industry which returned 3.6% over the past year.
Return vs Market: CREO underperformed the UK Market which returned 23.4% over the past year.
Stable Share Price: CREO is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CREO's weekly volatility (4%) has been stable over the past year.
About the Company
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues.
Creo Medical Fundamentals Summary
|CREO fundamental statistics|
Is CREO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CREO income statement (TTM)|
|Cost of Revenue||UK£5.39m|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-215.46%|
How did CREO perform over the long term?See historical performance and comparison
Is Creo Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CREO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CREO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CREO is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: CREO is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CREO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CREO is overvalued based on its PB Ratio (4.5x) compared to the GB Medical Equipment industry average (3.8x).
How is Creo Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CREO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CREO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CREO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CREO's revenue (41.9% per year) is forecast to grow faster than the UK market (5.4% per year).
High Growth Revenue: CREO's revenue (41.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CREO's Return on Equity is forecast to be high in 3 years time
How has Creo Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CREO is currently unprofitable.
Growing Profit Margin: CREO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CREO is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.
Accelerating Growth: Unable to compare CREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CREO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).
Return on Equity
High ROE: CREO has a negative Return on Equity (-32.35%), as it is currently unprofitable.
How is Creo Medical's financial position?
Financial Position Analysis
Short Term Liabilities: CREO's short term assets (£60.5M) exceed its short term liabilities (£21.8M).
Long Term Liabilities: CREO's short term assets (£60.5M) exceed its long term liabilities (£8.9M).
Debt to Equity History and Analysis
Debt Level: CREO's debt to equity ratio (16.5%) is considered satisfactory.
Reducing Debt: CREO's debt to equity ratio has increased from 0.9% to 16.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CREO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CREO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 24.6% each year.
What is Creo Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CREO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CREO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CREO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CREO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CREO's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Craig Gulliford (50 yo)
Mr. Craig Jonathan Gulliford serves as the Chief Executive Officer of Creo Medical Limited since 2012. Mr. Gulliford served as Operations Director of Vix ACIS Limited (formerly ACIS Holdings Ltd). Mr. Gull...
CEO Compensation Analysis
Compensation vs Market: Craig's total compensation ($USD1.30M) is above average for companies of similar size in the UK market ($USD743.64K).
Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.
Experienced Management: CREO's management team is seasoned and experienced (7.4 years average tenure).
Experienced Board: CREO's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CREO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Creo Medical Limited's employee growth, exchange listings and data sources
- Name: Creo Medical Limited
- Ticker: CREO
- Exchange: AIM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£280.454m
- Shares outstanding: 158.00m
- Website: https://creomedical.com
Number of Employees
- Creo Medical Limited
- Unit 2, Creo House
- Beaufort Park
- NP16 5UH
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 17:44|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.